1
Myelodysplastic–myeloproliferative diseases (Medical Condition)
Myelodysplastic–myeloproliferative diseases (Medical Condition)
DATE: 2015/06/06::
2
Expert Perspectives: Myeloproliferative Neoplasms & Myelodysplastic Syndromes
Expert Perspectives: Myeloproliferative Neoplasms & Myelodysplastic Syndromes
DATE: 2014/10/02::
3
Dr. Bart L. Scott - Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
Dr. Bart L. Scott - Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
DATE: 2012/08/01::
4
“Masked” Polycythemia vera: Time to change WHO diagnostic criteria
“Masked” Polycythemia vera: Time to change WHO diagnostic criteria
DATE: 2015/05/15::
5
Expert Perspectives: Myeloproliferative Neoplasms & MDS
Expert Perspectives: Myeloproliferative Neoplasms & MDS
DATE: 2014/06/02::
6
Blood Cancers Explained: Leukemia, Myeloma, Lymphoma, and more
Blood Cancers Explained: Leukemia, Myeloma, Lymphoma, and more
DATE: 2015/05/19::
7
Dr. Frederick Appelbaum - Treatment of Acute Myeloid Leukemia Evolving from Myelodysplasia
Dr. Frederick Appelbaum - Treatment of Acute Myeloid Leukemia Evolving from Myelodysplasia
DATE: 2012/08/01::
8
When and How to Use Iron Chelation Therapy in MDS
When and How to Use Iron Chelation Therapy in MDS
DATE: 2015/05/15::
9
Understanding MDS/MPN Overlap Syndrome
Understanding MDS/MPN Overlap Syndrome
DATE: 2014/02/17::
10
Weili Sun, MD, PHD, Hematology-Oncology at The Saban Research Institute - CHLA
Weili Sun, MD, PHD, Hematology-Oncology at The Saban Research Institute - CHLA
DATE: 2015/03/23::
11
Dr. John K Camoriano - Living Well with Blood Disorders - Fred Hutchinson Cancer Research Center
Dr. John K Camoriano - Living Well with Blood Disorders - Fred Hutchinson Cancer Research Center
DATE: 2012/08/01::
12
MPN Transformation to MDS and AML: Risk factors, therapy and outcomes
MPN Transformation to MDS and AML: Risk factors, therapy and outcomes
DATE: 2015/05/15::
13
5q Minus Syndrome: What we know (and what we don
5q Minus Syndrome: What we know (and what we don't know yet)
DATE: 2015/05/15::
14
Friday Satellite Symposium: MDS and MDS/MPN: Past, Present, and Future
Friday Satellite Symposium: MDS and MDS/MPN: Past, Present, and Future
DATE: 2014/09/09::
15
What are myeloproliferative disorders?
What are myeloproliferative disorders?
DATE: 2014/09/28::
16
Debate: Survival benefit of JAK2 inhibitors in Myelofibrosis
Debate: Survival benefit of JAK2 inhibitors in Myelofibrosis
DATE: 2015/06/07::
17
Current Understanding of a Genetic/Epigenetic Basis of Classic MPNs
Current Understanding of a Genetic/Epigenetic Basis of Classic MPNs
DATE: 2015/05/15::
18
Diagnosis, Prognosis, and Therapy of True ET vs. Prefibrotic MF
Diagnosis, Prognosis, and Therapy of True ET vs. Prefibrotic MF
DATE: 2015/05/15::
19
Kids helping Kids
Kids helping Kids
DATE: 2015/03/03::
20
THIS THING CALLED CANCER WHAT DO I DO
THIS THING CALLED CANCER WHAT DO I DO
DATE: 2015/04/18::
21
Dr. H. Joachim Deeg - Hematopoietic Cell Transplantation for Myelofibrosis
Dr. H. Joachim Deeg - Hematopoietic Cell Transplantation for Myelofibrosis
DATE: 2012/08/01::
22
Bright Red Awareness Video - Lee
Bright Red Awareness Video - Lee's Story
DATE: 2013/09/12::
23
Stem Cell Transplant for Myelofibrosis in the JAK2 Inhibitor Era
Stem Cell Transplant for Myelofibrosis in the JAK2 Inhibitor Era
DATE: 2015/05/15::
24
Beyond JAK2 Inhibitors: New targets and new agents
Beyond JAK2 Inhibitors: New targets and new agents
DATE: 2015/05/15::
25
Understanding the Natural History of Myelodysplastic/ Myeloproliferative Neoplasm (MDS/MPN)
Understanding the Natural History of Myelodysplastic/ Myeloproliferative Neoplasm (MDS/MPN)
DATE: 2015/02/09::
26
Role of Microenvironment in MPN
Role of Microenvironment in MPN
DATE: 2015/05/15::
27
Hydroxyurea Intolerance/Resistance in Polycythemia vera
Hydroxyurea Intolerance/Resistance in Polycythemia vera
DATE: 2015/05/15::
28
Myelodysplastic syndrome
Myelodysplastic syndrome
DATE: 2014/05/07::
29
Advances in Hematology: Mario Cazzola, MD
Advances in Hematology: Mario Cazzola, MD
DATE: 2014/02/21::
30
Carl’s Reality Show 1
Carl’s Reality Show 1
DATE: 2015/01/24::
31
Expert Perspectives: MPN & MDS
Expert Perspectives: MPN & MDS
DATE: 2015/06/08::
32
Dr. Steven D. Gore - Non-transplant Therapy for MDS
Dr. Steven D. Gore - Non-transplant Therapy for MDS
DATE: 2012/08/01::
33
Treating adult leukemia: Dr. David Steensma| Dana-Farber Cancer Institute
Treating adult leukemia: Dr. David Steensma| Dana-Farber Cancer Institute
DATE: 2012/05/10::
34
Mutations in MF: Which to test for, when and why
Mutations in MF: Which to test for, when and why
DATE: 2015/05/15::
35
Dr. Lauri M. Burroughs - Acquired Aplastic Anemia
Dr. Lauri M. Burroughs - Acquired Aplastic Anemia
DATE: 2012/08/01::
36
Diagnosis and Therapy of CMML in 2015
Diagnosis and Therapy of CMML in 2015
DATE: 2015/05/15::
37
Carl’s Reality Show 2
Carl’s Reality Show 2
DATE: 2015/01/24::
38
Inadequate or Loss of Response to Ruxolitinib, and Combination Strategies
Inadequate or Loss of Response to Ruxolitinib, and Combination Strategies
DATE: 2015/05/15::
39
Rapid Heme Panel Video – Dana-Farber/Brigham and Women
Rapid Heme Panel Video – Dana-Farber/Brigham and Women's Cancer Center
DATE: 2015/05/26::
40
BHC Nurses myeloproliferative diseases (MPD)
BHC Nurses myeloproliferative diseases (MPD)
DATE: 2008/08/31::
41
Dr. Anneclaire J. De Roos - Epidemiology - Fred Hutchinson Cancer Research Center
Dr. Anneclaire J. De Roos - Epidemiology - Fred Hutchinson Cancer Research Center
DATE: 2012/08/01::
42
Carl’s Reality Show 3
Carl’s Reality Show 3
DATE: 2015/01/23::
43
New insights into the myeloproliferative neoplasms
New insights into the myeloproliferative neoplasms
DATE: 2013/04/12::
44
Meet Dr. Paul Hendrie, Hematology Oncology Specialist
Meet Dr. Paul Hendrie, Hematology Oncology Specialist
DATE: 2015/01/15::
45
Understanding Efficacy of Azacitidine in Different MDS Subgroups
Understanding Efficacy of Azacitidine in Different MDS Subgroups
DATE: 2015/05/15::
46
Current Status of Risk Stratification of Patients with MDS
Current Status of Risk Stratification of Patients with MDS
DATE: 2015/05/15::
47
National MDS Day, 2014: Q & A with Dr Steven Lane
National MDS Day, 2014: Q & A with Dr Steven Lane
DATE: 2014/07/16::
48
Debate: Position of JAK2 inhibitors as second line therapy in Polycythemia vera
Debate: Position of JAK2 inhibitors as second line therapy in Polycythemia vera
DATE: 2015/06/07::
49
Prof Claire Harrison at ASH 2014: Highlights on myeloproliferative neoplasms
Prof Claire Harrison at ASH 2014: Highlights on myeloproliferative neoplasms
DATE: 2014/12/18::
50
Biography - Dr. Todd L. Rosenblat
Biography - Dr. Todd L. Rosenblat
DATE: 2015/02/27::
NEXT >>
RESULTS [51 .. 101]
From Wikipedia, the free encyclopedia
Jump to: navigation, search
Myelodysplastic-myeloproliferative diseases
Classification and external resources
MeSH D054437

Myelodysplastic–myeloproliferative diseases are a category of hematological malignancies disorders created by the World Health Organization which have characteristics of both myelodysplastic and myeloproliferative conditions.

When a hematological malignancy is characterised by normal differentiation of cells of myeloid cell line, it is referred to as myeloproliferative. On the other hand, when there is abnormal differentiation of cells of myeloid cell line, it is referred to as myelodysplastic.

External links[edit]


Wikipedia content is licensed under the GFDL License
Powered by YouTube
MASHPEDIA
LEGAL
  • Mashpedia © 2015